Axonics Modulation Technologies
Irvine
California
United States
154 articles about Axonics Modulation Technologies
-
Axonics® Provides Survey Results from Physician Seminar Series Showcasing the Recently FDA Approved Axonics r-SNM® System
12/9/2019
326 Physicians, Representing Nearly a Third of the Top 1,000 SNM Implanters in the U.S., Attended Axonics-Sponsored Seminars over the Past Two Months
-
Health Canada Approves Full-Body MRI Labeling for the Axonics® Sacral Neuromodulation System
12/2/2019
Axonics Modulation Technologies, Inc. announced Health Canada approved the use of full-body magnetic resonance imaging using 1.5 and 3 Tesla MRI scanners for patients implanted with the Axonics r-SNM System.
-
Axonics® Announces Closing of $110 Million Public Offering of Common Stock
11/22/2019
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 5,000,000 shares of common stock at the offering price of $22 per share.
-
Axonics® Announces Agreement to Supply its Sacral Neuromodulation System to The University of Tennessee Medical Center
11/21/2019
Axonics Modulation Technologies, Inc. announced that it has entered into an agreement to supply the Axonics r-SNM® System to The University of Tennessee Medical Center in Knoxville, Tennessee.
-
Axonics® Announces Pricing of Public Offering of Common Stock - Nov. 20, 2019
11/20/2019
Axonics Modulation Technologies, Inc. announced the pricing of its public offering of 5,000,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions.
-
Axonics® Announces Proposed Public Offering of Common Stock
11/19/2019
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $110,000,000 in shares of its common stock.
-
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications
11/14/2019
Axonics Modulation Technologies, Inc. announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration for the clinical indications of overactive bladder and urinary retention.
-
Axonics® Announces Third Quarter 2019 Financial Results and Operational Update
11/14/2019
Financial results for the third quarter ended September 30, 2019, and provided an update on operational initiatives.
-
Axonics® to Report 2019 Third Quarter and Nine-Month Financial Results and Host a Conference Call on November 14
11/7/2019
Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation devices, announced that it will release financial results for the third quarter and first nine months of 2019, and provide an update on U.S.
-
Axonics® Responds to Patent Action by Medtronic
11/5/2019
Believes Claims are Without Merit and an Attempt to Suppress Innovation and Competition
-
Axonics® Provides Update on U.S. Launch Activities
10/15/2019
Approximately 300 Physicians Registered to Attend Axonics-sponsored Seminars Showcasing Recently FDA-Approved1 Axonics r-SNM® System
-
Axonics® Broadens EU Commercial Footprint with Recommendation for Reimbursement in France and Supply Contract in Norway
10/7/2019
Axonics Modulation Technologies, Inc. announced it achieved two milestones that expand its commercial reach in France and Norway.
-
Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting
10/3/2019
Axonics Modulation Technologies, Inc. announced the presentation of detailed one-year results from its ARTISAN-SNM pivotal study at a plenary session at the joint scientific meeting of the American Urogynecologic Society and the International Urogynecological Association.
-
Axonics® Announces Exclusive Agreement to Supply Sacral Neuromodulation Systems to Leading Urology Practice Group
10/2/2019
Axonics Modulation Technologies, Inc. announced that it has entered into an exclusive agreement to supply the Axonics r-SNM® System to Adult Pediatric Urology and Urogynecology, headquartered in Omaha, Nebraska.
-
Axonics® to Exhibit its Sacral Neuromodulation System at the AUGS/IUGA Joint Scientific Meeting on September 24 – 28 in Nashville
9/24/2019
One-year Pivotal Study Results from ARTISAN-SNM to be Presented at Plenary Session
-
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
9/9/2019
Axonics Modulation Technologies, Inc. announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration.
-
Axonics® to Present at Upcoming Investor Conferences - Aug. 27, 2019
8/27/2019
Axonics Modulation Technologies, Inc. announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors
-
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
8/5/2019
Axonics Modulation Technologies, Inc. reported financial results for the second quarter ended June 30, 2019, and provided an update on operational initiatives.
-
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
8/1/2019
Axonics Modulation Technologies, Inc. announced completion of 1-year follow-ups and top-line clinical results from its ARTISAN-SNM pivotal clinical study conducted under an U.S. Food & Drug Administration Investigational Device Exemption designed to evaluate the safety and efficacy of the Axonics r-SNM® System1.
-
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
7/29/2019
Axonics Modulation Technologies, Inc. a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, announced the results from its ARTISAN-SNM study were published online in the peer-reviewed Journal of Urology.